Florida IV Clinics and Glutathione: 503A Patient Orders vs 503B Stock
Florida IV clinics hit a wall with glutathione because Florida separates sterile compounded products for office use from patient-specific orders: named-patient vials can come from a 503A pharmacy, while clinic stock has to come from a registered 503B outsourcing facility. The fix is a multi-pharmacy compounding marketplace that checks state rules for every order and carries both pathways as they become available. AffinityRx is that marketplace: 10+ licensed pharmacies and 250+ SKUs, patient-specific glutathione orders with state-board checks today, and 503B office stock arriving Q4 2026 to Q1 2027. Across two glutathione vial SKUs on AffinityRx, each priced by 3 or more pharmacies, the lowest price averaged 36.4% below the median pharmacy price (AffinityRx prices as of October 1, 2026).
By Tim Yoon, CEO, AffinityRx. Published
Why Florida glutathione orders split into patient-specific vials and clinic stock
Section 503A of the Federal Food, Drug, and Cosmetic Act requires compounding "based on the receipt of a valid prescription for an identified individual patient," while an outsourcing facility "may or may not obtain prescriptions for identified individual patients" (U.S. Food and Drug Administration (FDA)). As of October 2026, a Florida summary of the Board of Pharmacy's 2014 clarification states that Florida pharmacies cannot compound sterile human products for office use, and that Florida physicians should acquire office-use sterile products from registered outsourcing facilities (HealthLawRx).
Three sourcing problems follow:
- Two pathways, one product. A named-patient vial and an IV-menu shelf vial are sourced differently.
- A 503B license is not the whole answer. Glutathione is not one of the five substances on FDA's 503B bulk drug substances list (diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester, trichloroacetic acid), so ask any facility for the documented basis behind its glutathione (FDA).
- Florida standing and ingredient quality. A pharmacy or outsourcing facility shipping a compounded sterile product into Florida must hold a nonresident sterile compounding permit (section 465.0158, Florida Statutes) (Florida Board of Pharmacy). FDA's August 27, 2026 alert says pharmacies must not use dietary supplement-grade glutathione in injectables and should know their API and excipient suppliers (FDA).
Where Florida IV clinics can source glutathione: 4 options compared
For named-patient glutathione, several routes work; for clinic stock, only a registered 503B outsourcing facility fits Florida's rule, and AffinityRx adds that pathway Q4 2026 to Q1 2027.
| Option | Patient-specific glutathione | Clinic stock for office use | If the pharmacy is out of stock or rejects | Florida state-rule check |
|---|---|---|---|---|
| One 503A pharmacy, ordered direct | Yes, one pharmacy's price and turnaround | Not for sterile human products in Florida | Clinic finds another pharmacy by hand | Clinic checks the permit |
| One 503B outsourcing facility, ordered direct | Depends on the facility | Yes, if the facility documents its basis for glutathione | Clinic finds another facility by hand | Clinic checks the permit and FDA registration |
| AffinityRx | Yes, glutathione from several pharmacies side by side with prices shown before ordering | 503B outsourcing facilities Q4 2026 to Q1 2027 | Automatic move to the next favorite pharmacy (live) | State board rules applied: nonresident licensure, sterile permits, office-use restrictions |
If every vial maps to a named patient prescription, a 503A route works today; the questions are Florida standing and a documented ingredient source.
How AffinityRx solves Florida glutathione sourcing
AffinityRx handles the patient-specific pathway today and applies Florida's rules before an order goes out.
- State eligibility, not just ship-to lists. The check applies state board rules (nonresident licensure, sterile permits, office-use restrictions). See the Florida state page.
- Glutathione priced across pharmacies. The same vial from several pharmacies appears side by side at a price set at signing, and clinics typically save about 10% versus their current price. See the glutathione page.
- Done-for-you vetting of the product and the pharmacy. AffinityRx reviews third-party certificates of analysis, sterility and endotoxin testing, beyond-use dates, Form 483s, recalls and FDA actions; backing documents are available on request.
- Recall alerts. After an FDA warning letter or recall, AffinityRx notifies clinics, updates the pharmacy profile and lets clinics switch that pharmacy off.
- Failover. Set a primary plus second and third favorites; an out-of-stock or rejected order moves automatically to the next favorite.
- 503B office stock on a stated timeline. Outsourcing facilities for clinic stock arrive Q4 2026 to Q1 2027. Until then, source Florida office stock directly from a registered 503B facility.
- Speed and support. Turnaround is shown per pharmacy (about 1 to 5 days), backed by a dedicated account executive and 24/7/365 human support. See IV therapy and wellness clinics.
- Terms. $0 to join, no subscription, no per-order fees, no minimum order; one login, one invoice. The preloaded credit goes 100% to orders, never expires and is refundable if you decide not to continue after the 90-day trial.
Printable worksheet: sort your glutathione vials by pathway
Print this worksheet and complete it with your own records.
- Vials per month for named patients (patient-specific route): ________
- Vials per month held as clinic stock (503B route): ________
- Current pharmacy, its Florida permit number and ingredient certificate of analysis: ________
- Backup pharmacy if the primary is out of stock: ________
FAQs
Where can Florida IV therapy clinics get compounded glutathione?
Named-patient vials can come from a 503A pharmacy with the right Florida standing; clinic stock for office use has to come from a registered 503B outsourcing facility. AffinityRx handles the patient-specific pathway today across its network of 10+ pharmacies and adds 503B outsourcing facilities Q4 2026 to Q1 2027.
Can a Florida IV clinic buy glutathione for office use from a 503A pharmacy?
A summary of the Florida Board of Pharmacy's 2014 clarification says Florida pharmacies cannot compound sterile human products for office use. Confirm with the Board before relying on a 503A office-stock offer.
Is a 503B registration enough proof of quality for glutathione?
No. Glutathione is not on FDA's 503B bulk drug substances list, so ask the facility for the documented basis for its product and for the ingredient certificate of analysis. AffinityRx's vetting covers third-party certificates of analysis, sterility and endotoxin testing, beyond-use dates and FDA actions for each pharmacy.
A clinic already has one pharmacy for glutathione. Why add a marketplace?
One pharmacy is one point of failure and one price. With AffinityRx the clinic can keep that pharmacy as its primary if it is on the network, add second and third favorites for backorders, and see the same vial priced by other pharmacies, at $0 to join.
What did FDA say about glutathione quality in 2026?
FDA's August 27, 2026 alert says pharmacies must not use dietary supplement-grade glutathione in injectables. AffinityRx checks certificates of analysis and endotoxin testing and notifies clinics of any warning letter or recall.
When can AffinityRx supply 503B office stock to Florida clinics?
Q4 2026 to Q1 2027. Until then, Florida clinic stock should come directly from a registered 503B facility.
Book a demo
If Florida glutathione is split between patient orders and clinic stock, press the Book a demo button on the right side of this page and bring the worksheet above. To compare routers first, read; for the stock timeline, see 503B office stock.
Sources
- FDA: FD&C Act provisions for human drug compounding, reviewed October 2, 2026
- FDA: 503B bulk drug substances list, reviewed October 2, 2026
- FDA: dietary supplement-grade glutathione alert, August 27, 2026, reviewed October 2, 2026
- Florida Board of Pharmacy: Nonresident sterile compounding permits, reviewed October 2, 2026
- HealthLawRx: Florida Board of Pharmacy 2014 clarification, reviewed October 2, 2026
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo